Market Place
Sourcing Support
ProMIS Neurosciences Reveals Private Placement Financing
28 Jul 2025 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
26 Jul 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Reports Positive Phase 1a Alzheimer`s Trial Data
26 Jul 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Q1 2024 Results, Highlights
14 May 2024 //
GLOBENEWSWIRE
ProMIS Publishes ALS Treatment Research in Journal of Biological Chemistry
09 Apr 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
04 Apr 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Full Year 2023 Financial Results
01 Apr 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
11 Mar 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
22 Feb 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Issues Letter to Shareholders
08 Jan 2024 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Publication on Novel Target for ALS
20 Dec 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
08 Sep 2023 //
GLOBENEWSWIRE
ProMIS to Present at H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
21 Aug 2023 //
GLOBENEWSWIRE
ProMIS Announces Second Quarter 2023 Financial Results and Recent Highlights
14 Aug 2023 //
GLOBENEWSWIRE
ProMIS Showcases Data at Alzheimers Association International Conference 2023
17 Jul 2023 //
GLOBENEWSWIRE
ProMIS Announces Completion of Continuance
14 Jul 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange
10 Jul 2023 //
GLOBENEWSWIRE
ProMIS Holds Annual Meeting of Shareholders All Resolutions Approved
30 Jun 2023 //
GLOBENEWSWIRE
Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29
29 Jun 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces 1Q 2023 FYR Results and Recent Highlights
15 May 2023 //
GLOBENEWSWIRE
ProMIS Presents Preclinical Highlighting Targeting Toxic Misfolded Proteins
24 Apr 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Abstracts Accepted for Presentation
13 Mar 2023 //
GLOBENEWSWIRE
Promis Neuro to Present at the Oppenheimer 33rd Annual Healthcare Conference
08 Mar 2023 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces 3Q 2022 Financial Results and Recent Highlights
14 Nov 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement
12 Oct 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Second Quarter 2022 Financial
15 Aug 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences to Present at 2022 AAIC
27 Jul 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol "PMN"
08 Jul 2022 //
GLOBENEWSWIRE
Promis Announces Reverse Share Split To Meet Nasdaq Listing Criteria
27 Jun 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Debt Amendment and Conversion
22 Jun 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares
22 Jun 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Filing of Form 10 Registration Statement
22 Jun 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences presents at the 2022 Neuro4D International Conference
17 May 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces First Quarter 2022 Results
13 May 2022 //
GLOBENEWSWIRE
ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved
13 May 2022 //
GLOBENEWSWIRE
CORRECTION: ProMIS Neurosciences Announces First Quarter 2022 Results
13 May 2022 //
GLOBENEWSWIRE
ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items
03 May 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Reports New Milestones for Amyotrophic Lateral Sclerosis
28 Apr 2022 //
GLOBENEWSWIRE
ProMIS appoints experienced industry veteran Larry Altstiel as CMO
19 Apr 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Presents at the 2022 AAN
07 Apr 2022 //
GLOBENEWSWIRE
ProMIS Files Management Information Circular with Meeting of Shareholders
07 Apr 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences to Present at the 10th Annual NDD Summit
24 Mar 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Presents Preclinical Results of its Alzheimer`s Vaccine
22 Mar 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences says FY 2021 Results
17 Mar 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences to Present at the 2022 International Conference on AD/PD
10 Mar 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences PMN310 antibody demonstrates significant cognitive benefit
02 Mar 2022 //
GLOBENEWSWIRE
ProMIS Appoints Dr. Cheryl Wellington to its Scientific Advisory Board
27 Jan 2022 //
GLOBENEWSWIRE
ProMIS Announces Antibody Program for Schizophrenia Therapy
18 Jan 2022 //
GLOBENEWSWIRE
ProMIS to Participate in the Biotech Showcase 2022 Virtual Panel Discussion
07 Jan 2022 //
GLOBENEWSWIRE
ProMIS to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference
06 Jan 2022 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Third Quarter 2021 Results
12 Nov 2021 //
GLOBENEWSWIRE
ProMIS Neurosciences appoints new CEO and COO
22 Oct 2021 //
SEEKINGALPHA
ProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum
15 Sep 2021 //
GLOBENEWSWIRE
ProMIS Neurosciences to Participate in H.C. Wainwright & Co.
13 Sep 2021 //
GLOBENEWSWIRE
ProMIS Neurosciences appoints Josh Mandel-Brehm, to its Board of Directors
01 Sep 2021 //
GLOBENEWSWIRE
ProMIS Neurosciences Closes Upsized US$20,125,000 Public Offering
25 Aug 2021 //
GLOBENEWSWIRE
ProMIS Neurosciences Announces Upsize of Previously Announced Public Offering
18 Aug 2021 //
GLOBENEWSWIRE
ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units
17 Aug 2021 //
GLOBENEWSWIRE
